Skip to main content

Table 1 Histopathologic features of breast cancer xenografts and genomic correlation between primary tumor and xenograft

From: Molecular profiling of patient-derived breast cancer xenografts

Tumor xenograft Phenotype (IHC) Patient/xenograft Histology Pearson's correlation coefficient
HBCx-3 ER+/ER+ IDC 0.76
HBCx-5 HER2+/HER2+ IDC 0.35
HBCx-6 TN/TN IDC 0.60
HBCx-7 TN/TN ILC 0.23
HBCx-8 TN/TN IDC 0.82
HBCx-10 TN/TN IDC 0.57
HBCx-11 TN/TN IDC 0.65
HBCx-12A TN/TN IDC 0.66
HBCx-13A HER2+/HER2+ IDC 0.86
HBCx-15 TN/TN IDC 0.57
HBCx-16 TN/TN IDC 0.46
HBCx-17 TN/TN IDC 0.39
HBCx-20 ER+/ER+ IDC 0.87
HBCx-21 ER+PR+/ER+PR+ IDC 0.86
HBCx-22 ER+ PR+/ER+PR+ IDC 0.68
HBCx-23 TN/TN IDC 0.80
HBCx-24 TN/TN IDC 0.77
HBCx-31 TN/TN IDC 0.86
  1. ER, estrogen receptor; HBC, human breast cancer; HBC-n, HBC primary tumor n; HBCx-n, HBC xenograft tumor n; HER, human epidermal growth factor receptor; IDC, invasive ductal carcinoma; IHC, immunohistochemistry; ILC; invasive lobular carcinoma; PR, progesterone receptor; TN, triple-negative. List of xenografts used in the study according to the breast cancer subtype. Expression of HER2; ER and PR was determined by IHC. Pearson's correlation coefficients between pairs of patient tumors and xenografts were calculated between the clone status (Gain, Normal, Loss) of the same probe.